2017 - January 6th - "Evaluation for Inherited Prostate Cancer: Implications for Genetic Counseling"
"Evaluation for Inherited Prostate Cancer: Implications for Genetic Counseling" presented on January 6th, 2017 by Veda N. Giri, MD (IC 2016) during City of Hope's Division of Clinical Cancer Genetics Community of Practice Weekly Topics in Cancer Genetics Research (TICGR)."
Veda Giri, MD
Associate Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center
Thomas Jefferson University
Veda N. Giri, MD is an Associate Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University. She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. Dr. Giri has recently assumed the position of Director of Cancer Risk Assessment and Clinical Cancer Genetics at Thomas Jefferson University, where her role will be to lead an integrated and comprehensive effort in inherited cancer risk assessment and conduct studies focused on genetic evaluation of cancer risk. Her clinical efforts will be focused on genetic evaluation of inherited risk for GU cancers, specifically prostate, kidney, and upper tract urothelial cancers. Research studies will encompass genetic characterization of cancer risk using sequencing technologies, molecular signatures, and novel biomarkers to ultimately reduce cancer-related morbidity and mortality. Her research also has a strong focus in cancer disparities.
Dr. Giri received her medical degree from Jefferson Medical College, and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in cancer risk assessment and prostate cancer genetics.